Compare Trump Media and Technology Group Corp (DJT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs BIO-TECHNE Corp — how do they compare? Trump Media and Technology Group Corp trades at $8.96 (market cap $2.60B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 4.3× Trump Media and Technology Group Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| DJT | TECH | |
|---|---|---|
Market Cap | $2.60B | $11.24B |
Sector | Media | Health |
52-Week High | $18.50 | $72.29 |
52-Week Low | $7.06 | $43.31 |
Enterprise Value | $2.55B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $10.21, up 3.24% today, with technical indicators showing a bullish trend. The company reported a net loss of $238.1 million in Q2 2026 (Reuters, 2026-08-11) on minimal revenue of under $2 million, with losses driven by digital asset declines. Cash flow trends show improvement from 2025 to 2026, with net cash flow turning positive at $133 million in 2026. The company recently launched Truth API, a paid data service offering early access to market-moving social media posts.
Despite technical strength, DJT faces severe fundamental challenges with negative profit margins and mounting losses. Investment opportunity exists if the new data licensing business gains traction, but risks include continued operational losses, digital asset volatility, and dependence on political sentiment. The stock remains highly speculative with Wall Street showing limited analyst coverage.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
